Company / Cash & Equivalents
ROCKET PHARMACEUTICALS, INC. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$77.6M
FY2025
5-year range
$55.9M / $232.7M
FY2021-FY2025
Trend
-52.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $56M in FY2023 to $297M in FY2020.
Based on SEC 10-K filings.
$78M in FY2025 with a 5-year CAGR of -23.6%.
Improved from $56M to $78M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -18.0%
- 5-Year CAGR
- -23.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -23.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 52.6% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.6M | -52.6% |
| FY2024 | $163.6M | +192.7% |
| FY2023 | $55.9M | -60.2% |
| FY2022 | $140.5M | -39.6% |
| FY2021 | $232.7M | -21.7% |
| FY2020 | $297.1M | +60.3% |
| FY2019 | $185.4M | +66.5% |
| FY2018 | $111.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026